| Ticker |
ANRO
|
| CIK | 0001999480 |
| SIC | 2834 |
| Sector | Manufacturing |
| Industry Category | Pharmaceutical Products |
| Industry Group | Pharmaceutical Preparations |
| Address | 650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW, CA, 94041 |
| Website | www.altoneuroscience.com |
| Phone | 773-255-5012 |
| CEO | Amit Etkin |
| Employees | N/A |
Our team will help you customize a package that meets the needs of your business.
Request a Consultation|
Standardized FinancialsdocsIntrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals. For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards. Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics: |
|||||||||||||||||||||
|
Income Statement
|
Balance Sheet
|
||||||||||||||||||||
|
Cash Flow Statement
|
Calculations
|
||||||||||||||||||||
|
Latest NewsdocsIntrinio provides up-to-date news articles on every US company from various sources. Here are several examples: |
Alto Neuroscience Presents New Data at the Society of Biological Psychiatry Annual Meeting Underscoring Precision Psychiatry ApproachMOUNTAIN VIEW, Calif., April 28, 2025--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced multiple presentations at the Society of Biological Psychiatry (SOBP) Annual Meeting, in Toronto, Canada, held April 24-26, 2025. Alto Neuroscience to Participate in the JonesResearch Virtual CNS DayMOUNTAIN VIEW, Calif., April 22, 2025--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company management team will present at the JonesResearch Virtual CNS Day on Tuesday, April 29, 2025, at 12:30 pm ET and participate in one-on-one investor meetings. Metagenomi Leads The Charge With These 3 Penny StocksAs U.S. markets navigate the complexities of tariff negotiations and economic uncertainty, investors are keeping a close eye on potential opportunities within various sectors. Penny stocks, often representing smaller or newer companies, continue to pique interest due to their potential for both value and growth—despite being an older term in the investment lexicon. In this article, we explore three penny stocks that stand out for their robust financials and growth prospects, offering... Alto Neuroscience initiated with a Buy at H.C. WainwrightH.C. Wainwright analyst Patrick Trucchio initiated coverage of Alto Neuroscience (ANRO) with a Buy rating and $10 price target Alto is redefining neuropsychiatric drug development through the application of precision medicine in psychiatry, a “paradigm-shifting approach” that targets biomarker-defined patient populations, the analyst tells investors in a research note. The firm believes the company’s “differentiated” Precision Psychiatry Platform has the potential to optimize patient-treatment m Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business HighlightsMOUNTAIN VIEW, Calif., March 20, 2025--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the full-year ended December 31, 2024, and highlighted recent progress across its pipeline of clinical-stage product candidates. |
